MAP1LC3A and Alzheimer disease: DAM have been found to upregulate triggering receptor expressed on myeloid cells 2 (TREM2), Clec7a, and ApoE [14, 15] as well as engulf and autophagically degrade Aβ via LC3-associated endocytosis (LANDO) in the early stages of AD [16].